120 related articles for article (PubMed ID: 17446016)
1. Effect of injection routes on pharmacokinetics and lactone/carboxylate equilibrium of 9-Nitrocamptothecin in rats.
Chen J; Ping Q; Guo J; Liu M; Cai B
Int J Pharm; 2007 Aug; 340(1-2):29-33. PubMed ID: 17446016
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of lactone, carboxylate and total 9-nitrocamptothecin with different doses and administration routes in rats.
Chen J; Ping Q; Guo J; Chu X; Song M
Biopharm Drug Dispos; 2006 Mar; 27(2):53-9. PubMed ID: 16299828
[TBL] [Abstract][Full Text] [Related]
3. [In vitro and in vivo stability of 9-nitrocamptothecin lactone form in rats].
Chen J; Ping QN; Guo JX; Liu L; Chu XZ; Song MM
Yao Xue Xue Bao; 2005 Oct; 40(10):888-92. PubMed ID: 16408803
[TBL] [Abstract][Full Text] [Related]
4. 9-nitrocamptothecin polymeric nanoparticles: cytotoxicity and pharmacokinetic studies of lactone and total forms of drug in rats.
Dadashzadeh S; Derakhshandeh K; Shirazi FH
Anticancer Drugs; 2008 Sep; 19(8):805-11. PubMed ID: 18690092
[TBL] [Abstract][Full Text] [Related]
5. Liquid chromatographic quantitation of the lactone and the total of lactone and carboxylate forms of 9-nitrocamptothecin in human plasma.
Derakhshandeh K; Dadashzadeh S
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Apr; 818(2):199-204. PubMed ID: 15734159
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat.
Yang X; Hu Z; Chan SY; Goh BC; Duan W; Chan E; Zhou S
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Jul; 821(2):221-8. PubMed ID: 15936253
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of 9-nitro-20(S)-camptothecin in rats.
Zhong DF; Li K; Xu JH; Du Y; Zhang YF
Acta Pharmacol Sin; 2003 Mar; 24(3):256-62. PubMed ID: 12617776
[TBL] [Abstract][Full Text] [Related]
8. Urinary and biliary disposition of the lactone and carboxylate forms of 20(S)-camptothecin in rats.
Scott DO; Bindra DS; Sutton SC; Stella VJ
Drug Metab Dispos; 1994; 22(3):438-42. PubMed ID: 8070321
[TBL] [Abstract][Full Text] [Related]
9. Lactone stability and tissue distribution of free and liposomal encapsulated 9-nitrocamptothecin in rats following intravenous injection.
Chen J; Cai B; Ping Q; Liu M; Guo J
Drug Dev Ind Pharm; 2008 Aug; 34(8):853-9. PubMed ID: 18686092
[TBL] [Abstract][Full Text] [Related]
10. Preparation, characterization and biodistribution of the lactone form of 10-hydroxycamptothecin (HCPT)-loaded bovine serum albumin (BSA) nanoparticles.
Yang L; Cui F; Cun D; Tao A; Shi K; Lin W
Int J Pharm; 2007 Aug; 340(1-2):163-72. PubMed ID: 17482779
[TBL] [Abstract][Full Text] [Related]
11. Biliary excretion of irinotecan and its metabolites.
Itoh T; Takemoto I; Itagaki S; Sasaki K; Hirano T; Iseki K
J Pharm Pharm Sci; 2004 Jan; 7(1):13-8. PubMed ID: 15144730
[TBL] [Abstract][Full Text] [Related]
12. Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice.
Lu JL; Wang JC; Zhao SX; Liu XY; Zhao H; Zhang X; Zhou SF; Zhang Q
Eur J Pharm Biopharm; 2008 Aug; 69(3):899-907. PubMed ID: 18434109
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of camptothecins administered orally.
Liehr JG; Ahmed AE; Giovanella BC
Ann N Y Acad Sci; 1996 Dec; 803():157-63. PubMed ID: 8993508
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice.
Schluep T; Cheng J; Khin KT; Davis ME
Cancer Chemother Pharmacol; 2006 May; 57(5):654-62. PubMed ID: 16133526
[TBL] [Abstract][Full Text] [Related]
15. Comparative disposition of the antineoplastic agent 9-nitrocampotothecin and the inactive isomer 12-nitro camptothecin in CASE-bearing nude mice: effect of route of administration on tissue distribution.
Ahmed AE; Jacob S; Giovanella BC; Kozielski AJ; Liehr JG; Stehlin JS
Cancer Chemother Pharmacol; 1997; 41(1):29-36. PubMed ID: 9443611
[TBL] [Abstract][Full Text] [Related]
16. Plasma pharmacokinetics of lactone and carboxylate forms of 20(S)-camptothecin in anesthetized rats.
Scott DO; Bindra DS; Stella VJ
Pharm Res; 1993 Oct; 10(10):1451-7. PubMed ID: 8272406
[TBL] [Abstract][Full Text] [Related]
17. Plasma pharmacokinetics of 7-ethyl-10-hydroxycamptothecin (SN-38) after intravenous administration of SN-38 and irinotecan (CPT-11) to rats.
Kaneda N; Hosokawa Y; Yokokura T; Awazu S
Biol Pharm Bull; 1997 Sep; 20(9):992-6. PubMed ID: 9331983
[TBL] [Abstract][Full Text] [Related]
18. Effect of hydroxypropyl-beta-cyclodextrin-complexation and pH on solubility of camptothecin.
Saetern AM; Nguyen NB; Bauer-Brandl A; Brandl M
Int J Pharm; 2004 Oct; 284(1-2):61-8. PubMed ID: 15454297
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of guanosine in rats following intravenous or intramuscular administration of a 1:1 mixture of guanosine and acriflavine, a potential antitumor agent.
Shin DH; Choi KS; Cho BS; Song S; Moon DC; Hong JT; Lee CK; Chung YB
Arch Pharm Res; 2008 Oct; 31(10):1347-53. PubMed ID: 18958427
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novel camptothecin analog, in refractory cancer patients in a bridging phase I study.
Chatterjee A; Digumarti R; Katneni K; Upreti VV; Mamidi RN; Mullangi R; Surath A; Srinivas ML; Uppalapati S; Jiwatani S; Srinivas NR
J Clin Pharmacol; 2005 Apr; 45(4):453-60. PubMed ID: 15778426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
